Orion Symdax
Executive Summary
FDA's Cardiovascular & Renal Drugs Advisory Committee will meet Oct. 15 to consider levosimendan (NDA 20-967) in conjunction with conventional therapy for the intravenous treatment of patients with decompensated heart failure. On Oct. 14 the committee will discuss acute coronary syndromes. The meeting will begin both days at 9 a.m. in NIH's Masur Auditorium in Bethesda, Md
FDA's Cardiovascular & Renal Drugs Advisory Committee will meet Oct. 15 to consider levosimendan (NDA 20-967) in conjunction with conventional therapy for the intravenous treatment of patients with decompensated heart failure. On Oct. 14 the committee will discuss acute coronary syndromes. The meeting will begin both days at 9 a.m. in NIH's Masur Auditorium in Bethesda, Md. |